FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

CSL shares (ASX: CSL) have given holders something to smile about over the past month, off the back of a hugely difficult year in public markets. The CSL share price has clawed back 27.66% from early ...

NKGen Biotech, Inc. (OTC: NKGN) ('NKGen” or the 'Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...

NIH's All of Us Research Programme is now the largest integrated genomics and health database in the world: Maryland Thursday, July 2, 2026, 16:00 Hrs [IST] The National Institute ...

Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

This cell-like structure can grow, feed, divide and compete. Researchers ponder what it means for the future of synthetic ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it ...

Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the ...

Canada is at the forefront of agricultural biotechnology, combining strong scientific capability with a regulatory system designed to encourage innovation. Farmers have already integrated GM crops ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...

FOXO Technologies Inc. (OTC: FOXO) ('FOXO” or the 'Company”), today announced that its previously approved reverse stock split (the 'Reverse Split”) of its Class A common stock ('Common Stock” and the ...

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...